How to design multi-target drugs

Tamás Korcsmáros, Máté S Szalay, Csaba Böde, István A Kovács, Péter Csermely
2007 Expert Opinion on Drug Discovery  
Despite improved rational drug design and a remarkable progress in genomic, proteomic and highthroughput screening methods, the number of novel, single-target drugs fell much behind expectations during the past decade. Multi-target drugs and combinatorial therapies multiply the number of pharmacologically relevant target molecules by introducing a set of indirect, networkdependent effects. Parallel with this low-affinity binding of multi-target drugs eases the constraints of druggability, and
more » ... gnificantly increases the size of the druggable proteome. These effects tremendously expand the number of potential drug targets, and will introduce novel classes of multi-target drugs with smaller side effects and toxicity. Here we review the recent progress in this field, compare possible network attack strategies, and propose several methods to find target-sets for multi-target drugs.
doi:10.1517/17460441.2.6.799 pmid:23488998 fatcat:gxlmf3t2yvddxm6rapf437pdf4